Cost-utility analysis of vaccination against HPV in Israel

Gary Michael Ginsberg, Menachem Fisher, Inbar Ben-Shahar, Jacob Bornstein

Research output: Contribution to journalArticlepeer-review

34 Scopus citations


Using WHO-CHOICE methodology, we calculated cost-utility ratios for various interventions (PAP smear, HPV-DNA testing, VIA and vaccination against HPV) at various frequencies to reduce the burden of cervical cancer and condyloma (in the case of the HPV vaccination) in Israel, which has a low prevalence of cervical cancer. Assuming non-waning efficacy, HPV vaccinations will become cost-effective, very cost-effective and cost saving when the cost per dose falls below $96.85, $50.42 and $27.20, respectively. Attempts should be made to raise compliancy with PAP smears from the current opportunistic 12.2-20.0% per annum either before and/or after the vaccination is introduced.

Original languageEnglish
Pages (from-to)6677-6691
Number of pages15
Issue number37-38
StatePublished - 17 Sep 2007
Externally publishedYes


  • Cervical cancer
  • Cost-utility analysis
  • Vaccination


Dive into the research topics of 'Cost-utility analysis of vaccination against HPV in Israel'. Together they form a unique fingerprint.

Cite this